Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. announced a conference call scheduled for November 9, 2023, to discuss its third-quarter 2023 financial results and recent business developments. The company is focused on developing antibody-based therapies targeting viral infectious diseases, including COVID-19 and others. Their approach includes using advanced technology in virology and antibody engineering aimed at creating effective therapies. Details about the call, including registration options for analysts and listeners, were provided in the announcement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is preparing to discuss promising financial results and business developments.
  • The company's focus on protecting vulnerable populations from viral diseases is laudable.
  • Innovative technology aims to develop long-lasting antibody therapies.

Full Press Release Details

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available in the investor section of the company’s website approximately two hours after the end of the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Gabriella Linville-Engler

Frequently Asked Questions

When will Invivyd host its conference call?

Invivyd will host its conference call on November 9, 2023, at 4:30 p.m. ET.

What will be discussed in the conference call?

The call will cover financial results for Q3 2023 and recent business highlights.

How can I access the webcast for the conference call?

Listeners can register for the webcast through a link provided by Invivyd.

What is Invivyd's main focus?

Invivyd is focused on delivering antibody-based therapies to protect from viral diseases.

Where can I find the replay of the webcast?

A replay will be available in the investor section of Invivyd's website shortly after.

Last updated: Nov 2, 2023